A Multicenter, Prospective, Observational, Open-label Study to Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod
Latest Information Update: 10 Oct 2025
At a glance
- Drugs Efgartigimod alfa (Primary) ; Efgartigimod alfa (Primary)
- Indications Myasthenia gravis
- Focus Therapeutic Use
- Acronyms OPTIMAGE
Most Recent Events
- 24 Sep 2025 Status changed from not yet recruiting to recruiting.
- 01 Aug 2025 New trial record